Exploring 3 High Growth Tech Stocks in the United States

Over the last 7 days, the market has dropped 3.4%, but over the longer term, it has risen by 20% in the last year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks that can capitalize on these trends is crucial for investors seeking robust returns.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Sarepta Therapeutics	24.22%	44.94%	★★★★★★
TG Therapeutics	28.39%	43.54%	★★★★★★
Super Micro Computer	20.49%	27.13%	★★★★★★
Ardelyx	27.44%	65.92%	★★★★★★
G1 Therapeutics	27.57%	57.75%	★★★★★★
Invivyd	42.91%	70.39%	★★★★★★
Ascendis Pharma	39.71%	68.43%	★★★★★★
Travere Therapeutics	26.68%	68.81%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

ADMA Biologics (NasdaqGM:ADMA)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases, with a market cap of $4.28 billion.

Operations: ADMA Biologics generates revenue primarily from its ADMA Biomanufacturing segment, which contributes $326.70 million, and its Plasma Collection Centers, contributing $3.41 million.

ADMA Biologics has shown notable growth, with revenue increasing 14.8% annually and earnings projected to grow at an impressive 26.0% per year. Their recent Q2 results highlighted a significant sales jump to $107.19 million from $60.12 million the previous year, alongside net income of $32.06 million compared to a net loss of $6.37 million last year, reflecting robust operational performance despite a one-off loss of $29M impacting their financials over the past 12 months ending June 30, 2024. The company repaid $30M from its revolving credit facility, reducing total gross debt to $105M and demonstrating strong cash management capabilities. In terms of R&D expenditure, ADMA's commitment is evident with substantial investments driving innovation in plasma-derived therapeutics—a critical segment for future growth prospects in biotech industries focusing on rare diseases and immune deficiencies—ensuring that they stay ahead in this competitive market space while fostering long-term value creation for stakeholders through strategic financial maneuvers and enhanced revenue forecasts exceeding previous guidance by significant margins for fiscal years 2024 and 2025 ($400M+ and $445M+, respectively).

• Take a closer look at ADMA Biologics' potential here in our health report.

• Examine ADMA Biologics' past performance report to understand how it has performed in the past.

Madrigal Pharmaceuticals (NasdaqGS:MDGL)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for treating non-alcoholic steatohepatitis (NASH) in the United States and has a market cap of $5.18 billion.

Operations: Madrigal Pharmaceuticals specializes in developing treatments for non-alcoholic steatohepatitis (NASH) within the United States. As a clinical-stage biopharmaceutical company, it is focused on advancing its therapeutic pipeline to address this liver disease.

Madrigal Pharmaceuticals is poised for substantial growth, with revenue expected to surge 56.1% annually, outpacing the US market's 8.6%. Despite reporting a net loss of $151.97 million in Q2 2024, the company's R&D expenses underscore its commitment to innovation in liver disease treatments. With earnings projected to grow at an impressive 68.12% per year, Madrigal's strategic focus on research and development could drive future profitability and industry leadership.

• Click here to discover the nuances of Madrigal Pharmaceuticals with our detailed analytical health report.

• Learn about Madrigal Pharmaceuticals' historical performance.

MediaAlpha (NYSE:MAX)

Simply Wall St Growth Rating: ★★★★★★

Overview: MediaAlpha, Inc., through its subsidiaries, operates an insurance customer acquisition platform in the United States with a market cap of approximately $1.20 billion.

Operations: MediaAlpha, Inc. generates revenue primarily through its Internet Information Providers segment, amounting to $496.67 million. The company focuses on facilitating insurance customer acquisition in the U.S.

MediaAlpha's revenue surged to $178.27 million in Q2 2024, a notable rise from $84.77 million the previous year, reflecting its robust technology platform connecting major insurance carriers with high-intent shoppers. The company projects a further 22.7% annual revenue growth, outpacing the US market's 8.6%. R&D expenses have been significant, emphasizing innovation; they totaled $12 million in Q2 alone. Additionally, earnings are forecasted to grow at an impressive 61.31% annually over the next three years.

• Delve into the full analysis health report here for a deeper understanding of MediaAlpha.

• Explore historical data to track MediaAlpha's performance over time in our Past section.

Taking Advantage

• Click this link to deep-dive into the 249 companies within our US High Growth Tech and AI Stocks screener.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com